Labiana Health

Labiana Health OCF/Debt

The Operating Cash Flow to Debt Ratio of Labiana Health (LAB.MC) as of Oct 31, 2026 is 5.70 %. In the previous year, Operating Cash Flow to Debt Ratio was 26.75 % — a change of -78.69% (lower).

OCF/Debt

5.70 %

YoY

-78.69%

Last updated:

Operating Cash Flow to Debt Ratio of Labiana Health is 2025 5.70 % . Operating Cash Flow to Debt Ratio of Labiana Health was 2024 26.75 % . It decreases by -78.69% lower compared to the previous year.

The Labiana Health OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
12.44 EUR
Jan 1, 2019
-4.21 EUR
Jan 1, 2021
16.63 EUR
Jan 1, 2022
32.72 EUR
Jan 1, 2023
-6.15 EUR
Jan 1, 2024
26.75 EUR
Jan 1, 2025
5.70 EUR
The Labiana Health OCF/Debt history
YEAROCF/DebtYoY
5.70 %-78.69%
26.75 %-534.87%
-6.15 %-118.80%
32.72 %+96.80%
16.63 %-495.20%
-4.21 %-133.82%
12.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Operating Cash Flow to Debt Ratio of Labiana Health is 5.70 % in 2025.

Operating Cash Flow to Debt Ratio of Labiana Health changed from 26.75 % to 5.70 %, representing a -78.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Labiana Health since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Labiana Health with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Labiana Health

All Key Metrics — Labiana Health